I-131 therapy for metastatic thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)

I-131 therapy for metastatic thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen) - I-131 therapy for metastatic thyroid cancer with recombinant human thyroid-stimulating hormone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013970

Enrollment

Registered

2014-05-16

Start date

2014-05-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

recombinant human thyroid-stimulating hormone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a patient with distant metastases of thyroid cancer, who underwent total thyroidectomy or almost total thyroidectomy for differenciated thyroid cancer 2) a patient who underwent thyroidectomy before 6 weeks or more

Exclusion criteria

Exclusion criteria: 1) a patient whose thyroid Ca has not able to uptake I-131 2) a patient with clitical disease 3) a patient who was administered an iodinated contrast agent 4) pregnant female and feeding female 5) when medical staff determine that treatment can not be properly carried out

Design outcomes

Primary

Measure	Time frame
Assessment of anti-tumor effects with tumor uptake and tumor markers	—

Countries

Japan

Contacts

Public ContactAtsutaka Okizaki

Asahikawa Medical University Department of Radiology

okizaki@asahikawa-med.ac.jp+166-68-2572

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026